Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions

Area of Science:

• Oncology
• Cancer Biology
• Angiogenesis Research

Background:

• Tumours rely on new blood vessels (angiogenesis) for growth, often driven by vascular endothelial growth factor (VEGF) family ligands.
• Overexpression of VEGF in many solid cancers led to optimism for anti-angiogenic therapies targeting this pathway.
• VEGF-targeted drugs like bevacizumab have demonstrated efficacy in specific cancer types.

Purpose of the Study:

• To review the progress and challenges of VEGF-targeted anti-angiogenic therapy in oncology.
• To identify unresolved questions regarding treatment strategies, biomarkers, and resistance mechanisms.
• To discuss future directions for developing more effective and personalized anti-angiogenic treatments.

Main Methods:

• This study is a review of existing literature on VEGF-targeted therapy.
• It synthesizes information on clinical applications, treatment parameters, and resistance.
• It discusses future research needs in tumour vascularization and personalized medicine.

Main Results:

• VEGF pathway inhibitors have shown activity in certain cancers but are not universally effective.
• Unresolved questions include optimal use in different disease stages, chemotherapy interactions, and duration of therapy.
• Mechanisms of resistance, including paradoxical enhancement of tumour aggressiveness, require further investigation.

Conclusions:

• While VEGF-targeted therapies offer a valuable approach to anti-angiogenic treatment, their limitations highlight the need for deeper understanding.
• Further research into tumour vascularization complexities is crucial for developing more effective and personalized anti-angiogenic strategies.
• Addressing resistance mechanisms and identifying predictive biomarkers will enhance therapeutic outcomes.